

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid in Patients With Bone Metastases

JAMA - Journal of the American Medical Association

317, 48

DOI: [10.1001/jama.2016.19425](https://doi.org/10.1001/jama.2016.19425)

Citation Report

#	ARTICLE	IF	CITATIONS
1	An Evidence-Based Approach to Myeloma Bone Disease. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 109-118.	1.2	12
2	Zoledronic Acid Dosing Interval for Metastatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1477.	3.8	0
3	Zoledronic Acid Dosing Interval for Metastatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1477.	3.8	0
5	Evaluation and management of skeletal disease in cancer care. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 217-226.	2.0	12
7	Myeloma and Bone Disease. <i>Current Osteoporosis Reports</i> , 2017, 15, 483-498.	1.5	55
8	Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer. <i>Cancer Treatment Reviews</i> , 2017, 61, 23-34.	3.4	28
11	Should bone-targeted agents be standard of care in postmenopausal patients with early breast cancer?. <i>Breast Cancer Management</i> , 2017, 6, 1-7.	0.2	0
13	Reply to T.J. Powles et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2720-2721.	0.8	0
14	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology Cancer Care Ontario Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3978-3986.	0.8	127
15	Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 3949-3955.	0.8	57
16	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology Cancer Care Ontario Focused Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 822-824.	2.5	9
17	Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data. <i>Supportive Care in Cancer</i> , 2018, 26, 2833-2841.	1.0	13
18	Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 229-238.	0.9	8
19	Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. <i>Journal of Bone Oncology</i> , 2018, 11, 1-9.	1.0	26
20	Bone: best papers of the year 2017. <i>Archives of Osteoporosis</i> , 2018, 13, 29.	1.0	0
21	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
22	Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 585.	3.4	1
23	Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer—Reply. <i>JAMA Oncology</i> , 2018, 4, 586.	3.4	1

#	ARTICLE	IF	CITATIONS
24	Bones in Multiple Myeloma: Imaging and Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 638-646.	1.8	30
25	Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases. Journal of Clinical Oncology, 2018, 36, 1051-1051.	0.8	5
26	De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times?. Journal of Oncology Practice, 2018, 14, 465-467.	2.5	5
27	Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. Asian Journal of Andrology, 2018, 20, 215.	0.8	14
28	Hypericin targets osteoclast and prevents breast cancer-induced bone metastasis via NFATc1 signaling pathway. Oncotarget, 2018, 9, 1868-1884.	0.8	21
29	Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 812-818.	0.8	85
30	Use of Bone-Modifying Agents in Myeloma and Bone Metastases: How Recent Dosing Interval Studies Have Affected Our Practice. Journal of Oncology Practice, 2018, 14, 457-464.	2.5	12
31	Reply to L. Kennedy et al. Journal of Clinical Oncology, 2018, 36, 1052-1053.	0.8	2
32	Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer. Current Breast Cancer Reports, 2018, 10, 241-250.	0.5	10
33	Efficacy and safety of de-escalation bone-modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis. Cancer Management and Research, 2018, Volume 10, 3809-3823.	0.9	6
34	Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US. Clinical Epidemiology, 2018, Volume 10, 1349-1358.	1.5	11
35	Duration of adjuvant immunotherapy—biologic, clinical and economic considerations. Medical Oncology, 2018, 35, 160.	1.2	9
37	How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive. Frontiers in Immunology, 2018, 9, 262.	2.2	91
38	Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 461-472.	2.0	13
39	Paraganglioma as a risk factor for bone metastasis. Endocrine Journal, 2018, 65, 253-260.	0.7	3
40	The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres. Canadian Urological Association Journal, 2018, 12, .	0.3	5
41	Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 2270-2290.	0.8	224
42	How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. Critical Reviews in Oncology/Hematology, 2019, 142, 68-75.	2.0	4

#	ARTICLE	IF	CITATIONS
43	Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides. , 2019, , 607-617.		0
44	Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma. Cancer Medicine, 2019, 8, 6945-6954.	1.3	5
45	Spectrophotometric and visual determination of zoledronic acid by using a bacterial cell-derived nanopaper doped with curcumin. Mikrochimica Acta, 2019, 186, 719.	2.5	9
46	<p>Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma</p>. OncoTargets and Therapy, 2019, Volume 12, 8467-8478.	1.0	9
47	Update Breast Cancer 2019 Part 5 â€“ Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1090-1099.	0.8	16
48	Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs. JAMA Network Open, 2019, 2, e199570.	2.8	13
49	Histological evaluation of the healing process of autografted mandibular bone defects in rats under treatment with zoledronate. Journal of Cranio-Maxillo-Facial Surgery, 2019, 47, 1779-1786.	0.7	1
50	Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2019, 9, 774.	1.3	5
51	Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. Cancers, 2019, 11, 1332.	1.7	28
52	Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers?. Breast Cancer: Basic and Clinical Research, 2019, 13, 117822341984350.	0.6	11
53	Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 22-28.	2.3	10
54	Prevention and Treatment of Skeletal Complications. , 2019, , 193-218.		0
55	Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 235-237.	1.2	12
56	The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. Critical Reviews in Oncology/Hematology, 2019, 139, 108-116.	2.0	17
57	De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2019, 176, 507-517.	1.1	23
58	Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. BJU International, 2019, 124, 373-382.	1.3	11
59	Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treatment Reviews, 2019, 76, 57-67.	3.4	85
60	Ambulatory status after surgical and nonsurgical treatment for spinal metastasis. Cancer, 2019, 125, 2631-2637.	2.0	32

#	ARTICLE	IF	CITATIONS
61	A patent review of bisphosphonates in treating bone disease. Expert Opinion on Therapeutic Patents, 2019, 29, 315-325.	2.4	19
62	US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology. JAMA Oncology, 2019, 5, 607.	3.4	7
63	Pain prevalence and treatment in patients with metastatic bone disease. Oncology Letters, 2019, 17, 3362-3370.	0.8	8
64	Optimal dosing of zoledronate to prevent fractures: improving riskâ€benefit balance. Journal of Internal Medicine, 2019, 286, 230-230.	2.7	0
65	Causes, Consequences, and Control of High Cancer Drug Prices. , 2019, , 39-57.		1
66	Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling. Pharmacological Research, 2019, 142, 140-150.	3.1	24
67	Bisphosphonates. Journal of Pain and Symptom Management, 2019, 57, 1018-1030.	0.6	6
68	Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. Current Hematologic Malignancy Reports, 2019, 14, 70-82.	1.2	16
69	Myeloma bone disease: from biology findings to treatment approaches. Blood, 2019, 133, 1534-1539.	0.6	88
70	Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration. Supportive Care in Cancer, 2019, 27, 3859-3867.	1.0	14
72	Mechanisms and treatment of bone pain in multiple myeloma. Current Opinion in Supportive and Palliative Care, 2019, 13, 408-416.	0.5	16
73	Pain Management in Patients with Multiple Myeloma: An Update. Cancers, 2019, 11, 2037.	1.7	38
74	Metastatic bone disease: Pathogenesis and therapeutic options. Journal of Bone Oncology, 2019, 15, 100205.	1.0	153
75	Bone Metastases; Medical Treatment. , 2019, , 320-328.		0
76	Incidence of skeletal related events in patients with bone metastasis receiving denosumab every four weeks compared to intervals greater than every four weeks. Journal of Oncology Pharmacy Practice, 2019, 25, 529-534.	0.5	2
78	Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany. Supportive Care in Cancer, 2020, 28, 2175-2184.	1.0	15
79	Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies. European Urology Focus, 2020, 6, 17-25.	1.6	4
80	Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations. World Journal of Urology, 2020, 38, 681-693.	1.2	12

#	ARTICLE	IF	CITATIONS
81	Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 37-47.	1.0	19
82	Role of bone-modifying agents in advanced cancer. <i>Annals of Palliative Medicine</i> , 2020, 9, 1314-1323.	0.5	5
83	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. <i>Journal of the National Cancer Institute</i> , 2020, 112, 698-707.	3.0	48
84	Management of bone complications in patients with genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 94-104.	0.8	1
85	Multiple Myeloma and Related Disorders. , 2020, , 1884-1910.e7.		4
86	Bone metabolism regulation: Implications for the treatment of bone diseases. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110494.	2.5	16
87	Bone metastases. <i>Nature Reviews Disease Primers</i> , 2020, 6, 83.	18.1	246
88	ABC4 Consensus: First Latin American Meeting's Assessment, Comments, and Application of Its Recommendations. <i>JCO Global Oncology</i> , 2020, 6, 819-827.	0.8	2
89	Older cancer patients and COVID-19 outbreak: Practical considerations and recommendations. <i>Cancer Medicine</i> , 2020, 9, 9193-9204.	1.3	17
90	Early palliative radiation versus observation for high-risk asymptomatic or minimally symptomatic bone metastases: study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 1115.	1.1	5
91	Controversies in the use of new bone-modifying therapies in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 1034-1043.	1.2	13
92	Impact of Extraskelatal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases. <i>Cancers</i> , 2020, 12, 2034.	1.7	5
93	Multiple Myeloma Associated Bone Disease. <i>Cancers</i> , 2020, 12, 2113.	1.7	35
94	Effect of Preoperative Zoledronic Acid Administration on Pain Intensity after Percutaneous Vertebroplasty for Osteoporotic Vertebral Compression Fractures. <i>Pain Research and Management</i> , 2020, 2020, 1-8.	0.7	13
95	Quantitative bone single photon emission computed tomography analysis of the effects of duration of bisphosphonate administration on the parietal bone. <i>Scientific Reports</i> , 2020, 10, 17461.	1.6	5
96	Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations. <i>Current Oncology</i> , 2020, 27, 270-274.	0.9	1
97	Pharmacologic management of metastatic bone disease. <i>Bone</i> , 2022, 158, 115735.	1.4	3
98	COVID-19 and myeloma: what are the implications for now and in the future?. <i>British Journal of Haematology</i> , 2020, 190, 173-178.	1.2	9

#	ARTICLE	IF	CITATIONS
99	Distribution and predictive value of initial presenting symptoms in spinal metastases from primary cancer patients. <i>European Spine Journal</i> , 2020, 29, 3148-3156.	1.0	2
100	Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1829-1845.	1.2	3
101	Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. <i>Neuroendocrinology</i> , 2021, 111, 207-216.	1.2	13
102	Supportive Care in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 56-61.	1.2	12
103	The limitations of today's clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1180-1189.	0.5	3
104	Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. <i>JCO Oncology Practice</i> , 2020, 16, 665-674.	1.4	44
105	Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1429-1440.	0.5	12
106	Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency. <i>Supportive Care in Cancer</i> , 2020, 28, 2533-2540.	1.0	17
107	Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany. <i>Supportive Care in Cancer</i> , 2020, 28, 5223-5233.	1.0	21
108	Treatment and disease-related complications in multiple myeloma: Implications for survivorship. <i>American Journal of Hematology</i> , 2020, 95, 672-690.	2.0	22
109	Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1736-1743.	0.8	44
110	Basic and clinical associations between bone and cancer. <i>Immunological Medicine</i> , 2020, 43, 103-106.	1.4	7
111	Rhein-PEG-nHA conjugate as a bone targeted drug delivery vehicle for enhanced cancer chemoradiotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 27, 102196.	1.7	16
112	Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. <i>Supportive Care in Cancer</i> , 2021, 29, 925-943.	1.0	28
113	A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2021, 142, 132-140.	1.3	42
114	Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non-Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases. <i>Annals of Pharmacotherapy</i> , 2021, 55, 697-704.	0.9	6
115	Nitrogen-containing bisphosphonate-loaded micro-arc oxidation coating for biodegradable magnesium alloy pellets inhibits osteosarcoma through targeting of the mevalonate pathway. <i>Acta Biomaterialia</i> , 2021, 121, 682-694.	4.1	16
116	Primary perivascular epithelioid cell tumor (PEComa) in bone: A review of the literature and a case arising in the humerus with multiple metastases. <i>Journal of Bone Oncology</i> , 2021, 26, 100336.	1.0	10

#	ARTICLE	IF	CITATIONS
117	Trading carefully in de-escalation for bone-targeted agents “ is less more, after all?. European Journal of Cancer, 2021, 142, 141-142.	1.3	0
118	Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer and Prostatic Diseases, 2021, 24, 341-348.	2.0	8
119	Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment. Seminars in Cancer Biology, 2021, 68, 175-185.	4.3	28
120	Therapy of Myeloma Bone Disease. , 2021, , 111-137.		0
121	Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings. Current Hematologic Malignancy Reports, 2021, 16, 40-44.	1.2	5
122	Review of Bone Modifying Agents in Metastatic Breast Cancer. Cureus, 2021, 13, e13332.	0.2	4
123	Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study. Journal of Oncology Pharmacy Practice, 2022, 28, 523-529.	0.5	1
124	Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics. Cells, 2021, 10, 433.	1.8	5
125	Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. JAMA Oncology, 2021, 7, 246.	3.4	34
126	Image-guided Cryotherapy for Musculoskeletal Tumors. Current Medical Imaging, 2021, 17, 166-178.	0.4	6
127	Management of Myeloma Bone Lesions. International Journal of Molecular Sciences, 2021, 22, 3389.	1.8	8
128	Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nature Communications, 2021, 12, 1714.	5.8	70
129	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e119-e130.	5.1	92
130	Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey. Breast Cancer Research and Treatment, 2021, 187, 477-486.	1.1	6
131	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 94, 102168.	3.4	6
132	Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation. Journal of Bone Oncology, 2021, 27, 100351.	1.0	4
133	Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCDC). JCO Global Oncology, 2021, 7, 559-571.	0.8	10
134	Clinical Efficacy and Safety of Zoledronic Acid Combined with PVP/ PKP in the Treatment of Osteoporotic Vertebral Compression Fracture: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BioMed Research International, 2021, 2021, 1-14.	0.9	5

#	ARTICLE	IF	CITATIONS
135	Bone-modifying Agents (BMAs) in Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e618-e630.	1.1	9
136	Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey. <i>Supportive Care in Cancer</i> , 2021, 29, 6903-6912.	1.0	6
137	Uptake of bone modifying agents in patients with HER2 + metastatic breast cancer with bone metastases – prospective data from a multi-site Australian registry. <i>Internal Medicine Journal</i> , 2021, , .	0.5	0
138	Integrating New Effectiveness Data Into US Food and Drug Administration’s Approved Drug Labeling. <i>JAMA Internal Medicine</i> , 2021, 181, 897-898.	2.6	5
139	Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1906-1913.	3.1	3
141	Myeloma Bone Disease: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6208.	1.8	25
142	Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies. <i>Current Osteoporosis Reports</i> , 2021, 19, 452-461.	1.5	0
143	The role of bone-modifying agents in myeloma bone disease. <i>JBMR Plus</i> , 2021, 5, e10518.	1.3	6
144	Oncological treatment of bone tumours and bone metastases. <i>Orthopaedics and Trauma</i> , 2021, 35, 163-169.	0.2	0
145	Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management. <i>Cells</i> , 2021, 10, 1377.	1.8	35
146	Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study. <i>European Journal of Cancer</i> , 2021, 157, 485-492.	1.3	7
147	Bone metastasis: mechanisms, therapies, and biomarkers. <i>Physiological Reviews</i> , 2021, 101, 797-855.	13.1	153
148	Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 812-822.	0.2	4
149	Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma. <i>JAMA Network Open</i> , 2021, 4, e2118410.	2.8	1
150	Current Overview of Treatment for Metastatic Bone Disease. <i>Current Oncology</i> , 2021, 28, 3347-3372.	0.9	52
151	Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations. <i>Journal of Bone Oncology</i> , 2021, 29, 100375.	1.0	9
152	Bone Health in Patients With Prostate Cancer: An Evidence-Based Algorithm. , 2021, 38, S20-S26.		2
153	Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research) <i>TJ ETQq1 1 0.784314 rgBT₁₁/Overlook</i> e41-e56.	0.2	11

#	ARTICLE	IF	CITATIONS
154	ADJUVANT THERAPIES IN METASTATIC BONE DISEASE. Operative Techniques in Orthopaedics, 2021, 31, 100899.	0.2	0
155	Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. Journal of Bone Oncology, 2021, 30, 100388.	1.0	6
156	Recent therapeutic approaches in myeloma. , 2022, , 1019-1029.		0
157	Bone metastasesâ€™ current status of bone-targeted treatments. , 2022, , 957-966.		0
158	Therapies of bone metastases in castration-resistant prostate cancer. , 2022, , 967-975.		0
159	Bone Metastasis of Breast Cancer. Advances in Experimental Medicine and Biology, 2019, 1152, 105-129.	0.8	90
160	Zoledronate treatment duration is linked to bisphosphonateâ€™related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis. Oral Diseases, 2019, 25, 1116-1135.	1.5	22
161	How I treat a refractory myeloma patient who is not eligible for a clinical trial. Hematology American Society of Hematology Education Program, 2019, 2019, 125-136.	0.9	2
162	Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer. Endocrinology, Diabetes and Metabolism Case Reports, 2019, 2019, .	0.2	2
163	Impact of the COVID-19 Pandemic on the Urologistâ€™s clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 501-510.	0.7	59
164	Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis. Oncotarget, 2017, 8, 90308-90314.	0.8	5
165	Advances in treatment of metastatic breast cancer with bone metastasis. Chinese Clinical Oncology, 2018, 7, 31-31.	0.4	5
166	Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 445-456.	3.9	8
167	Supportive Treatments for Patients with Cancer. Deutsches Ärztblatt International, 2017, 114, 481-487.	0.6	32
168	Minimally effective concentration of zoledronic acid to suppress osteoclasts. Experimental and Therapeutic Medicine, 2018, 15, 5330-5336.	0.8	7
169	Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Medical Weekly, 2019, 149, w20031.	0.8	4
170	Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review. World Journal of Men's Health, 2020, 38, 151.	1.7	7
171	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 452-478.	2.3	848

#	ARTICLE	IF	CITATIONS
172	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1685-1717.	2.3	138
173	Supportive care in multiple myeloma: Current practices and advances. Cancer Treatment and Research Communications, 2021, 29, 100476.	0.7	5
174	Osteoporosis Management with Focus on Spine. , 2021, , 61-92.		0
175	Canadian Urologic Association best practice report: Bone health in prostate cancer. Canadian Urological Association Journal, 2021, 15, 375-382.	0.3	3
176	Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. Cancers, 2021, 13, 4978.	1.7	6
177	All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma. Journal of Bone Oncology, 2021, 31, 100399.	1.0	12
178	Mammakarzinom bei der alten und geriatrischen Patientin. , 2017, , 1-16.		0
179	Bone-Targeted Treatment in CRPC Management. , 2018, , 317-325.		0
180	Endokrines System und Immunmodulation. , 2018, , 721-796.		0
181	Mammakarzinom bei der alten und geriatrischen Patientin. , 2018, , 401-416.		0
182	Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents. Translational Cancer Research, 2018, 7, S81-S84.	0.4	3
183	Bone-Targeted Therapy in Advanced Breast Cancer. , 2019, , 557-563.		0
184	Effect of intravenous administration of zoledronic acid on jaw bone density in cases having skeletal metastasis: A prospective clinical study. Journal of Indian Prosthodontic Society, The, 2019, 19, 203.	0.3	2
185	Metastatic Bone Tumors. Orthopaedic Study Guide Series, 2019, , 159-164.	0.3	0
186	Upgrade pharmacotherapy for cancer pain. Onkologie (Czech Republic), 2019, 13, 73-77.	0.0	1
188	Systemic Therapies for Patients with Metastatic Spinal Disease. , 2020, , 513-522.		0
189	Enhancement of Cancer Chemotherapeutic Efficacy via Bone-Targeted Drug Delivery Carrier in Bone Metastases. Drug Design, Development and Therapy, 2021, Volume 15, 4455-4468.	2.0	3
190	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. Clinical Genitourinary Cancer, 2022, 20, 43-52.	0.9	3

#	ARTICLE	IF	CITATIONS
191	Skeletal-Related Events in Patients With Multiple Myeloma and Prostate Cancer Who Receive Standard vs Extended-Interval Bisphosphonate Dosing. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, S22-S26.	0.6	1
192	Fracture Risk Evaluation of Bone Metastases: A Burning Issue. <i>Cancers</i> , 2021, 13, 5711.	1.7	10
193	RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 635-636.	3.0	2
194	GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 397.	7.1	58
195	The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 2: breast cancer. <i>British Dental Journal</i> , 2022, 232, 95-100.	0.3	2
196	Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?. <i>Cancers</i> , 2022, 14, 440.	1.7	20
198	The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 3: prostate cancer. <i>British Dental Journal</i> , 2022, , .	0.3	1
199	Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval. <i>Journal of Bone Oncology</i> , 2022, 33, 100416.	1.0	21
200	Endokrines System und Immunmodulation. , 2022, , 799-885.		0
201	American Association of Oral and Maxillofacial Surgeons™ Position Paper on Medication-Related Osteonecrosis of the Jaws™ 2022 Update. <i>Journal of Oral and Maxillofacial Surgery</i> , 2022, 80, 920-943.	0.5	312
202	Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. <i>Current Oncology</i> , 2022, 29, 1709-1722.	0.9	7
203	Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1441-1460.	1.8	35
204	VEGF mitigates bisphosphonate-induced apoptosis and differentiation inhibition of MC3T3-E1 cells. <i>Experimental and Therapeutic Medicine</i> , 2021, 23, 130.	0.8	3
205	Bone-targeting agents in major solid tumour metastases: a multinational cohort study. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e1064-e1073.	0.8	0
206	Spinal metastasis: narrative reviews of the current evidence and treatment modalities. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210916.	0.4	11
207	Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study. <i>BioDrugs</i> , 2022, 36, 381-392.	2.2	2
209	Pharmacological Prevention and Management of Skeletal-Related Events and Bone Loss in Individuals with Cancer. <i>Seminars in Oncology Nursing</i> , 2022, 38, 151276.	0.7	3
210	Bigger isn't always better: the ESMO dose de-intensification guideline framework. <i>Annals of Oncology</i> , 2022, 33, 672-673.	0.6	0

#	ARTICLE	IF	CITATIONS
211	Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2022, 97, 1086-1107.	2.0	208
212	Controversial role of β_1 T cells in pancreatic cancer. <i>International Immunopharmacology</i> , 2022, 108, 108895.	1.7	7
213	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	40
214	The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. <i>Scandinavian Journal of Urology</i> , 2022, 56, 278-284.	0.6	10
215	Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review. <i>Journal of Bone Oncology</i> , 2022, 35, 100446.	1.0	37
216	Bone Disease in Multiple Myeloma: Biologic and Clinical Implications. <i>Cells</i> , 2022, 11, 2308.	1.8	13
217	The use of bone-modifying agents in multiple myeloma. <i>Blood Reviews</i> , 2023, 57, 100999.	2.8	2
218	Roadmap for New Practitioners to Navigate the Multiple Myeloma Landscape. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
219	Osteonkologie: Knochenmetastasen und Tumortherapie-induzierte Osteoporose. <i>Springer Reference Medizin</i> , 2022, , 1-23.	0.0	0
220	Biological and Clinical Aspects of Metastatic Spinal Tumors. <i>Cancers</i> , 2022, 14, 4599.	1.7	11
221	Roadmap for new practitioners to navigate the multiple myeloma landscape. <i>Heliyon</i> , 2022, 8, e10586.	1.4	0
223	Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective. <i>Cancer Management and Research</i> , 0, Volume 14, 3047-3062.	0.9	8
224	Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool. <i>Geriatrics (Switzerland)</i> , 2022, 7, 133.	0.6	1
225	Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. <i>European Journal of Cancer</i> , 2022, , .	1.3	0
227	AAOS Clinical Practice Guideline Summary: Treatment of Metastatic Carcinoma and Myeloma of the Femur. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2023, 31, e118-e129.	1.1	4
229	Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer. <i>BMC Medicine</i> , 2023, 21, .	2.3	5
230	Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications. <i>Cancers</i> , 2023, 15, 1518.	1.7	7
231	Bone marrow adipocytes induce cancer-associated fibroblasts and immune evasion, enhancing invasion and drug resistance. <i>Cancer Science</i> , 2023, 114, 2674-2688.	1.7	7

#	ARTICLE	IF	CITATIONS
232	Multicenter study on atypical femoral fractures in patients with bone metastases taking bone-modifying agents. Journal of Bone Oncology, 2023, , 100478.	1.0	1
237	Management of bone metastasis in prostate cancer. Journal of Bone and Mineral Metabolism, 2023, 41, 317-326.	1.3	2
242	Moderne Aspekte der Osteoprotektion â€“ Rationale und derzeitiger Status. , 2023, , 109-118.		0